Immunitybio Inc（IBRX）財務資料IBRXImmunitybio Inc

Evaluating the bottom line, ImmunityBio, Inc. maintains a gross margin of 99.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -120.41%, while the net margin is -449.63%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IBRX converts its operational activities into shareholder value.

In the context of the broader market, IBRX competes directly with industry leaders such as CYTK and PTGX. With a market capitalization of $8.71B, it holds a significant position in the sector. When comparing efficiency, IBRX's gross margin of 99.42% stands against CYTK's 80.46% and PTGX's 100.00%. Such benchmarking helps identify whether ImmunityBio, Inc. is trading at a premium or discount relative to its financial performance.

ImmunityBio has shown substantial revenue growth, with Q2 2026 revenue reaching $51,240,000, but continues to report significant net losses, including a net income loss of $230,378,000 in Q2 2026. The gross margin remains strong at around 99%, indicating effective cost management despite losses.